Lazertinib 240 mg 用于既往 EGFR 酪氨酸激酶抑制剂治疗后晚期 EGFR T790M 阳性非小细胞肺癌患者的 1/2 期研究
这项 1/2 期研究(NCT03046992)整合分析了 lazertinib 240 mg 在既往 EGFR TKI 治疗后晚期 EGFR T790M 阳性 NSCLC 患者中的疗效与安全性。78 例患者在韩国 17 个中心接受治疗,T790M 阳性者客观缓解率为 55.3%(95%CI:44.1-66.4),中位无进展生存期 11.1 个月(95%CI:5.5-16.4),中位总生存期未达到。
要点
- T790M 阳性患者客观缓解率为 55.3%(95%CI:44.1-66.4),其中完全缓解 1 例(1.3%)、部分缓解 41 例(53.9%)。
- 中位无进展生存期 11.1 个月(95%CI:5.5-16.4),中位总生存期未达到(中位随访 22.0 个月)。
- 可测量颅内病灶患者颅内客观缓解率为 85.7%(95%CI:59.8%-100.0%),3 例发生严重药物相关不良事件。
核心结论
- Lazertinib 240 mg/d 在既往 EGFR TKI 治疗后晚期 T790M 阳性 NSCLC 患者中具有可管理的安全性特征和持久的抗肿瘤疗效,包括脑转移。
研究设计与样本
- 1/2 期研究(NCT03046992)的整合分析,评估 lazertinib 在既往 EGFR TKI 治疗后晚期 EGFR T790M 阳性 NSCLC 患者中的疗效与安全性。
- 成人 EGFR 突变阳性 NSCLC 患者既往接受 EGFR 靶向 TKI 后进展,接受每日一次口服 lazertinib 240 mg 持续给药直至疾病进展。
- 禁止既往因 T790M 阳性 NSCLC 接受 TKI 治疗;主要终点为安全性和客观缓解率,次要终点包括无进展生存期、总生存期和颅内客观缓解率。
- 共 78 例患者在韩国 17 个中心接受 lazertinib 240 mg 治疗;基线 T790M 阳性肿瘤患者 N=76。
主要发现
- 基线 T790M 阳性肿瘤患者(N=76)中,完全缓解 1 例(1.3%),部分缓解 41 例(53.9%),客观缓解率 55.3%(95%CI:44.1-66.4)。
- 中位无进展生存期 11.1 个月(95%CI:5.5-16.4);中位总生存期未达到(中位随访 22.0 个月)。
- 可测量颅内病灶患者(n=7)中,颅内完全缓解 1 例(14.3%),部分缓解 5 例(71.4%),颅内客观缓解率 85.7%(95%CI:59.8%-100.0%)。
- 最常见的治疗中出现的不良事件为皮疹(37.2%)、瘙痒(34.6%)和感觉异常(33.3%),多数为轻至中度。
- 3 例患者发生严重药物相关不良事件(胃炎、肺炎、间质性肺炎);主要耐药机制为 EGFR T790M 缺失。
临床怎么用
- 原文结论为 lazertinib 240 mg/d 在既往 EGFR TKI 治疗后晚期 T790M 阳性 NSCLC 患者中具有可管理的安全性特征和持久的抗肿瘤疗效,包括脑转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This integrated analysis of a phase 1/2 study (NCT03046992) evaluated the efficacy and safety of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with advanced EGFR T790M-positive NSCLC after previous EGFR TKI therapy. METHODS: Adults with EGFR mutation-positive NSCLC that progressed after prior EGFR-directed TKIs received once daily oral lazertinib 240 mg continuously until disease progression. Prior TKIs to treat T790M-positive NSCLC were prohibited. Primary endpoints were safety and objective response rate (ORR). Secondary endpoints included progression-free survival, overall survival, and intracranial ORR. RESULTS: A total of 78 patients received lazertinib 240 mg at 17 centers in South Korea. Among patients with T790M-positive tumors at baseline (N = 76), one (1.3%) had a complete response and 41 (53.9%) had partial responses, giving an ORR of 55.3% (95% confidence interval [CI]: 44.1-66.4). Median progression-free survival was 11.1 months (95% CI: 5.5-16.4). Median overall survival was not reached (median follow-up = 22.0 mo). In patients with measurable intracranial lesions (n = 7), one (14.3%) had a complete intracranial response and five (71.4%) had partial responses, giving an intracranial ORR of 85.7% (95% CI: 59.8%-100.0%). The most common treatment-emergent adverse events were rash (37.2%), pruritus (34.6%), and paresthesia (33.3%); most were mild to moderate in severity. Serious drug-related adverse events occurred in three patients (gastritis, pneumonia, pneumonitis). The major mechanism of resistance was EGFR T790M loss. CONCLUSIONS: Lazertinib 240 mg/d has a manageable safety profile with durable antitumor efficacy, including brain metastases, in patients with advanced T790M-positive NSCLC after previous EGFR TKI therapy.
引用
- Cho BC, Han JY, Kim SW, et al. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2021. PMID: 34958928. doi:10.1016/j.jtho.2021.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。